High unbound fraction of valproic acid in a hypoalbuminemic critically ill patient on renal replacement therapy
- PMID: 21325101
- DOI: 10.1345/aph.1P308
High unbound fraction of valproic acid in a hypoalbuminemic critically ill patient on renal replacement therapy
Abstract
Objective: To describe a hypoalbuminemic critically ill patient with subtherapeutic total valproic acid serum concentrations but unbound valproic acid concentrations within normal limits.
Case summary: During an intensive care unit admission, a 61-year-old woman with urosepsis and multiorgan dysfunction syndrome developed tonic-clonic seizures with respiratory failure, and tracheal intubation was performed. An intravenous loading dose of valproic acid 1500 mg (25 mg/kg) was administered and therapy was continued with valproic acid 750 mg (12.5 mg/kg) twice daily. Because of progressive renal failure, continuous venovenous hemofiltration was started on day 3 of valproic acid therapy. On day 7 of valproic acid therapy, routine testing of serum valproic acid trough concentration returned as undetectable. Subsequent determinations of trough serum concentrations of total valproic acid showed values below the therapeutic range. Data from a full pharmacokinetic curve (multiple blood samples during a dosing interval) showed that the free fraction of valproic acid was >60%. Although total valproic acid concentrations were still low, the unbound concentrations were considered therapeutic. Serum albumin was 1.2 g/dL on the multiple sampling day.
Discussion: The patient's hypoalbuminemia probably explains the remarkably high free fraction of valproic acid. Our hypothesis is that the low albumin level was associated with high plasma clearance of valproic acid, leading to extremely low total drug concentrations. To our knowledge, this high percentage of free valproic acid has not been previously described.
Conclusions: Health-care professionals should be aware of the need of early determination of both total and free fraction valproic acid serum concentrations in hypoalbuminemic critically ill patients. Increasing the dose of valproic acid purely based on total valproic acid serum concentrations in this patient population should be avoided.
Similar articles
-
Acute seizures due to a probable interaction between valproic acid and meropenem.Ann Pharmacother. 2005 Mar;39(3):533-7. doi: 10.1345/aph.1E358. Epub 2005 Feb 8. Ann Pharmacother. 2005. PMID: 15701769
-
Total phenytoin concentrations do not accurately predict free phenytoin concentrations in critically ill children.Pediatr Crit Care Med. 2006 Sep;7(5):434-9; quiz 440. doi: 10.1097/01.PCC.0000235252.43921.DE. Pediatr Crit Care Med. 2006. PMID: 16885794
-
Acute seizures in a patient receiving divalproex sodium after starting ertapenem therapy.Pharmacotherapy. 2007 Aug;27(8):1202-5. doi: 10.1592/phco.27.8.1202. Pharmacotherapy. 2007. PMID: 17655519
-
Therapeutic drug monitoring of phenytoin in critically ill patients.Pharmacotherapy. 2008 Nov;28(11):1391-400. doi: 10.1592/phco.28.11.1391. Pharmacotherapy. 2008. PMID: 18956999 Review.
-
Valproate Protein Binding Is Highly Variable in ICU Patients and Not Predicted by Total Serum Concentrations: A Case Series and Literature Review.Pharmacotherapy. 2017 Apr;37(4):500-508. doi: 10.1002/phar.1912. Epub 2017 Mar 16. Pharmacotherapy. 2017. PMID: 28173638 Review.
Cited by
-
Clinical Pharmacokinetic Monitoring of Free Valproic Acid Levels: A Systematic Review.Clin Pharmacokinet. 2022 Oct;61(10):1345-1363. doi: 10.1007/s40262-022-01171-w. Epub 2022 Aug 30. Clin Pharmacokinet. 2022. PMID: 36040614
-
Clinical Consequences of Disproportionate Free Valproate Elevation in Critically Ill Adult Patients: A Multicenter Retrospective Cohort Study.Neurocrit Care. 2025 Mar 25:10.1007/s12028-025-02243-y. doi: 10.1007/s12028-025-02243-y. Online ahead of print. Neurocrit Care. 2025. PMID: 40133756
-
Antiepileptic Drug Removal by Continuous Renal Replacement Therapy: A Review of the Literature.Clin Drug Investig. 2017 Jan;37(1):7-23. doi: 10.1007/s40261-016-0457-0. Clin Drug Investig. 2017. PMID: 27587068 Review.
-
Development and Validation of a Risk Prediction Model for Acute Kidney Injury After the First Course of Cisplatin.J Clin Oncol. 2018 Mar 1;36(7):682-688. doi: 10.1200/JCO.2017.75.7161. Epub 2018 Jan 10. J Clin Oncol. 2018. PMID: 29320311 Free PMC article.
-
Role of Free Valproic Acid Levels in a Patient with Severe Hypoalbuminemia: A Case Report.Can J Hosp Pharm. 2022 Jul 4;75(3):239-242. doi: 10.4212/cjhp.3179. eCollection 2022 Summer. Can J Hosp Pharm. 2022. PMID: 35847470 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical